vorinostat has been researched along with Cancer of Cervix in 12 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data strongly indicate the high therapeutic potential of vorinostat in uterine sarcomas." | 7.76 | Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010) |
| "Our data strongly indicate the high therapeutic potential of vorinostat in uterine sarcomas." | 3.76 | Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010) |
| "Vorinostat is a histone deacetylase inhibitor (HDACi) that was demonstrated in our previous study to inhibit the proliferation, migration, and invasion of cervical cancer cells by regulating the PI3K/Akt signaling pathway." | 1.62 | Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. ( Cai, Y; Hsiao, WLW; Liang, H; Liu, C; Luo, D; Pan, B; Peng, F; Su, J; Xia, C; Yin, S, 2021) |
| "Vorinostat has good therapeutic efficacy against primary cutaneous T-cell lymphoma in the refractory stage." | 1.56 | Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. ( Cai, Y; He, Z; Liang, S; Xia, C, 2020) |
| "Cervical cancer is caused by a persistent infection of the mucosal epithelia with high-risk human papilloma viruses (HPVs)." | 1.51 | Nb-induced stabilisation of p53 in HPV-infected cells. ( Gettemans, J; Steels, A; Vannevel, L; Zwaenepoel, O, 2019) |
| "After human cervical cancer SiHa cells were treated with SAHA and cisplatin (DDP) of different concentrations, inhibition and apoptosis rates, and cell cycle were detected." | 1.42 | Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism. ( Han, P; Wang, H; Xin, M; Xing, J; Xu, S; Zhou, JL, 2015) |
| "Vorinostat (VOR) has been reported to enhance the cytotoxic effects of doxorubicin (DOX) with fewer side effects because of the lower DOX dosage in breast cancer cells." | 1.40 | Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. ( Hoe, KL; Hwang, SO; Kim, DU; Kim, JH; Lee, SJ; Nam, JH; Nam, M; Noh, EJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Steels, A | 1 |
| Vannevel, L | 1 |
| Zwaenepoel, O | 1 |
| Gettemans, J | 1 |
| Xia, C | 2 |
| He, Z | 1 |
| Cai, Y | 2 |
| Liang, S | 1 |
| Pan, B | 1 |
| Yin, S | 1 |
| Peng, F | 1 |
| Liu, C | 1 |
| Liang, H | 1 |
| Su, J | 1 |
| Hsiao, WLW | 1 |
| Luo, D | 1 |
| Lee, SJ | 1 |
| Hwang, SO | 1 |
| Noh, EJ | 1 |
| Kim, DU | 1 |
| Nam, M | 1 |
| Kim, JH | 1 |
| Nam, JH | 1 |
| Hoe, KL | 1 |
| You, BR | 1 |
| Park, WH | 1 |
| He, H | 1 |
| Liu, X | 1 |
| Wang, D | 1 |
| Wang, Y | 1 |
| Liu, L | 1 |
| Zhou, H | 1 |
| Luo, X | 1 |
| Wang, N | 1 |
| Ji, B | 1 |
| Luo, Y | 1 |
| Zhang, T | 1 |
| Huang, Z | 1 |
| Peng, S | 1 |
| Knoff, J | 1 |
| Lee, SY | 1 |
| Yang, B | 1 |
| Wu, TC | 1 |
| Hung, CF | 1 |
| Han, X | 1 |
| Wang, S | 1 |
| Zhou, W | 1 |
| Li, Y | 1 |
| Lei, W | 1 |
| Lv, W | 1 |
| Xing, J | 1 |
| Wang, H | 1 |
| Xu, S | 1 |
| Han, P | 1 |
| Xin, M | 1 |
| Zhou, JL | 1 |
| Lange, L | 1 |
| Hemmerich, P | 1 |
| Spänkuch, B | 1 |
| He, J | 1 |
| Huang, C | 1 |
| Tong, A | 1 |
| Chen, B | 1 |
| Zeng, Z | 1 |
| Zhang, P | 1 |
| Wang, C | 1 |
| Wei, Y | 1 |
| Hrzenjak, A | 1 |
| Moinfar, F | 1 |
| Kremser, ML | 1 |
| Strohmeier, B | 1 |
| Petru, E | 1 |
| Zatloukal, K | 1 |
| Denk, H | 1 |
12 other studies available for vorinostat and Cancer of Cervix
| Article | Year |
|---|---|
Nb-induced stabilisation of p53 in HPV-infected cells.
Topics: Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Female; HeLa Cells; Humans; Papillomaviridae; Pr | 2019 |
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fem | 2020 |
Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway.
Topics: Animals; Epithelial-Mesenchymal Transition; Female; HeLa Cells; Humans; Mice; Phosphatidylinositol 3 | 2021 |
Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Cell Survival; Chromati | 2014 |
Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Female; | 2014 |
SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells.
Topics: Alphapapillomavirus; Base Sequence; DNA Primers; DNA-Binding Proteins; Female; Genes, Viral; HeLa Ce | 2014 |
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
Topics: Animals; Antineoplastic Agents; Bortezomib; CD8-Positive T-Lymphocytes; Disease Models, Animal; Fema | 2015 |
Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer.
Topics: Adenoviridae; Animals; Drug Synergism; Female; HeLa Cells; Histone Deacetylase Inhibitors; Humans; H | 2015 |
Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism.
Topics: Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Line, Tumor; | 2015 |
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Caspase 3; Cell Cycle Protein | 2015 |
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.
Topics: Amino Acid Sequence; Antineoplastic Agents; Female; Gene Expression Profiling; Gene Expression Regul | 2008 |
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem | 2010 |